STRO-004 vs Tisotumab Vedotin Humax-tf-adc

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: Tissue Factor (TF) · full Non-Small Cell Lung Cancer pipeline

STRO-004

Developed by Sutro Biopharma, Inc.

Phase 1 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07227168 (registry estimate)

No aligned efficacy figure on record for this race.

Tisotumab Vedotin Humax-tf-adc · Tivdak

Marketed by Pfizer and partners

Phase 2 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT02001623 · Phase 1/2 · completed

This was an open-label, single-arm phase 1/2 safety study: 195 patients with advanced solid tumors all received tisotumab vedotin in dose-escalation cohorts (3–6 patients) and tumor-specific expansion cohorts, with no randomization, blinding, placebo, or active control. The primary endpoints were counts of treatment-emergent adverse events, so the results are descriptive safety/tolerability data only; there was no comparator arm or formal statistical comparison to establish efficacy. Because the design provides no controlled evidence of benefit, the evidence grade is weak.

Reported efficacy

Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events (Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.); Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events (Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.): Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events (Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.): Dose Escalation Part: 0.3 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 1 Participants; CTCAE Grade >=3 TEAEs: 2 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 0.6 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 1 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 3 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 0.9 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 0 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 1 Participants; TEAEs Related to Study Drug: 2 Participants | Dose Escalation Part: 1.2 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 1 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 1.5 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 2 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 1.8 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 3 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 2.0 mg/kg — TEAEs: 3 Participants; Serious TEAEs: 2 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 2 Participants; TEAEs Related to Study Drug: 3 Participants | Dose Escalation Part: 2.2 mg/kg — TEAEs: 6 Participants; Serious TEAEs: 4 Participants; Infusion-Related TEAEs: 0 Participants; CTCAE Grade >=3 TEAEs: 4 Participants; TEAEs Related to Study Drug: 6 Participants (not_applicable)

Result source: NCT02001623

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSTRO-004Tisotumab Vedotin Humax-tf-adc
PFS, median—Not reported4.2bn 41NCT02001623
20 other results
OS, median—Not reported—Not reported
ORR—Not reported24%bn 55NCT02001623
14 other results
Duration of response, median—Not reported4.3bn 13NCT02001623
3 other results

PFS, median

STRO-004
—Not reported
Tisotumab Vedotin Humax-tf-adc
4.2bn 41NCT02001623
20 other results

OS, median

STRO-004
—Not reported
Tisotumab Vedotin Humax-tf-adc
—Not reported

ORR

STRO-004
—Not reported
Tisotumab Vedotin Humax-tf-adc
24%bn 55NCT02001623
14 other results

Duration of response, median

STRO-004
—Not reported
Tisotumab Vedotin Humax-tf-adc
4.3bn 13NCT02001623
3 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

STRO-004: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. STRO-004: 0 of 4 rows · Tisotumab Vedotin Humax-tf-adc: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTisotumab Vedotin Humax-tf-adc
Dropout rate
100%2.2 mg/kga
NCT02001623 · Phase 1/2 · monotherapy
show 24 more results
100%2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100%1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100%1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
66.7%1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100%0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100%0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100%0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100%Dose Expansion Part: Bladder Cance
NCT02001623 · Phase 1/2 · monotherapy
96.4%Dose Expansion Part: Cervical Canc
NCT02001623 · Phase 1/2 · monotherapy
100%Dose Expansion Part: Endometrial C
NCT02001623 · Phase 1/2 · monotherapy
100%Dose Expansion Part: Esophageal Ca
NCT02001623 · Phase 1/2 · monotherapy
93.3%Dose Expansion Part: Non-Small Cel
NCT02001623 · Phase 1/2 · monotherapy
—Dose Expansion Part: Non-Small-Cel
NCT02001623 · Phase 1/2 · monotherapy
97.2%Dose Expansion Part: Ovarian Cance
NCT02001623 · Phase 1/2 · monotherapy
100%Dose Expansion Part: Prostate Canc
NCT02001623 · Phase 1/2 · monotherapy
n/a: no completion milestone
NCT03245736 · Phase 2 · registry result, not featured evidence
—3q4wk 1.2 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone3q4wk 0.9 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2 Cohort Expansion: Cohort 3
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2 Cohort Expansion: Cohort 5
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 1
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 2
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 4
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 6
NCT02552121 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
50%2.2 mg/kga
NCT02001623 · Phase 1/2 · monotherapy
show 24 more results
0%2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33.3%1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0%1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0%1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0%0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0%0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0%0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
26.7%Dose Expansion Part: Bladder Cance
NCT02001623 · Phase 1/2 · monotherapy
10.9%Dose Expansion Part: Cervical Canc
NCT02001623 · Phase 1/2 · monotherapy
28.6%Dose Expansion Part: Endometrial C
NCT02001623 · Phase 1/2 · monotherapy
0%Dose Expansion Part: Esophageal Ca
NCT02001623 · Phase 1/2 · monotherapy
20%Dose Expansion Part: Non-Small Cel
NCT02001623 · Phase 1/2 · monotherapy
—Dose Expansion Part: Non-Small-Cel
NCT02001623 · Phase 1/2 · monotherapy
13.9%Dose Expansion Part: Ovarian Cance
NCT02001623 · Phase 1/2 · monotherapy
33.3%Dose Expansion Part: Prostate Canc
NCT02001623 · Phase 1/2 · monotherapy
20%
NCT03245736 · Phase 2 · registry result, not featured evidence
—3q4wk 1.2 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
33.3%3q4wk 0.9 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2 Cohort Expansion: Cohort 3
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2 Cohort Expansion: Cohort 5
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 1
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 2
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 4
NCT02552121 · Phase 1/2 · registry result, not featured evidence
—Part 2: Cohort Expansion: Cohort 6
NCT02552121 · Phase 1/2 · registry result, not featured evidence
Serious AEs
66.7%2.2 mg/kga
NCT02001623 · Phase 1/2 · monotherapy
show 24 more results
66.7%2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
66.7%1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
66.7%1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
66.7%1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0%0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33.3%0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
66.7%0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
46.7%Dose Expansion Part: Bladder Cance
NCT02001623 · Phase 1/2 · monotherapy
47.3%Dose Expansion Part: Cervical Canc
NCT02001623 · Phase 1/2 · monotherapy
35.7%Dose Expansion Part: Endometrial C
NCT02001623 · Phase 1/2 · monotherapy
53.3%Dose Expansion Part: Esophageal Ca
NCT02001623 · Phase 1/2 · monotherapy
—Dose Expansion Part: Non-Small Cel
NCT02001623 · Phase 1/2 · monotherapy
40%Dose Expansion Part: Non-Small-Cel
NCT02001623 · Phase 1/2 · monotherapy
36.1%Dose Expansion Part: Ovarian Cance
NCT02001623 · Phase 1/2 · monotherapy
33.3%Dose Expansion Part: Prostate Canc
NCT02001623 · Phase 1/2 · monotherapy
—
NCT03245736 · Phase 2 · registry result, not featured evidence
33.3%3q4wk 1.2 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
33.3%3q4wk 0.9 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
0%Part 2 Cohort Expansion: Cohort 3
NCT02552121 · Phase 1/2 · registry result, not featured evidence
0%Part 2 Cohort Expansion: Cohort 5
NCT02552121 · Phase 1/2 · registry result, not featured evidence
81.8%Part 2: Cohort Expansion: Cohort 1
NCT02552121 · Phase 1/2 · registry result, not featured evidence
66.7%Part 2: Cohort Expansion: Cohort 2
NCT02552121 · Phase 1/2 · registry result, not featured evidence
40%Part 2: Cohort Expansion: Cohort 4
NCT02552121 · Phase 1/2 · registry result, not featured evidence
33.3%Part 2: Cohort Expansion: Cohort 6
NCT02552121 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
2.2 mg/kga
decreased appetite 83.3%
alopecia 66.7%
epistaxis 66.7%
NCT02001623 · Phase 1/2 · monotherapy
show 22 more results
2.0 mg/kg
alopecia 66.7%
arthralgia 66.7%
diarrhoea 66.7%
NCT02001623 · Phase 1/2 · monotherapy
1.8 mg/kg
epistaxis 100%
fatigue 100%
alopecia 66.7%
NCT02001623 · Phase 1/2 · monotherapy
1.5 mg/kg
epistaxis 66.7%
constipation 33.3%
flatulence 33.3%
NCT02001623 · Phase 1/2 · monotherapy
1.2 mg/kg
epistaxis 100%
anaemia 66.7%
arthralgia 66.7%
NCT02001623 · Phase 1/2 · monotherapy
0.9 mg/kg
stomatitis 66.7%
alanine aminotransferase increased 33.3%
anaemia 33.3%
NCT02001623 · Phase 1/2 · monotherapy
0.6 mg/kg
anaemia 100%
hypokalaemia 66.7%
muscle spasms 66.7%
NCT02001623 · Phase 1/2 · monotherapy
0.3 mg/kg
fatigue 100%
constipation 66.7%
diarrhoea 66.7%
NCT02001623 · Phase 1/2 · monotherapy
epistaxis 86.7%
fatigue 53.3%
conjunctivitis 46.7%
NCT02001623 · Phase 1/2 · monotherapy
fatigue 52.7%
epistaxis 50.9%
nausea 45.5%
NCT02001623 · Phase 1/2 · monotherapy
epistaxis 78.6%
fatigue 71.4%
alopecia 57.1%
NCT02001623 · Phase 1/2 · monotherapy
fatigue 66.7%
epistaxis 53.3%
nausea 46.7%
NCT02001623 · Phase 1/2 · monotherapy
epistaxis 73.3%
nausea 66.7%
fatigue 53.3%
NCT02001623 · Phase 1/2 · monotherapy
epistaxis 83.3%
nausea 55.6%
alopecia 52.8%
NCT02001623 · Phase 1/2 · monotherapy
fatigue 83.3%
epistaxis 66.7%
nausea 66.7%
NCT02001623 · Phase 1/2 · monotherapy
3q4wk 1.2 mg/kg
conjunctivitis 100%
epistaxis 83.3%
myalgia 83.3%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
3q4wk 0.9 mg/kg
epistaxis 100%
conjunctivitis 66.7%
decreased appetite 66.7%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
abdominal pain 100%
alopecia 100%
decreased appetite 100%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
abdominal discomfort 0%
abdominal pain 0%
abdominal pain lower 0%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
epistaxis 63.6%
fatigue 54.5%
alopecia 45.5%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
acute kidney injury 33.3%
alopecia 33.3%
anaemia 33.3%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
diarrhoea 80%
fatigue 80%
abdominal pain 60%
NCT02552121 · Phase 1/2 · registry result, not featured evidence
alopecia 66.7%
diarrhoea 66.7%
epistaxis 66.7%
NCT02552121 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tisotumab Vedotin Humax-tf-adc

ORR 0% (n=6)2.2 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT02001623 · Phase 1/2 · monotherapy
show 14 more results
0% (n=3)2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3)1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3)1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3)1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3)0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3)0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3)0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
27% (n=15)
NCT02001623 · Phase 1/2 · monotherapy
24% (n=55)
NCT02001623 · Phase 1/2 · monotherapy
7% (n=14)
NCT02001623 · Phase 1/2 · monotherapy
13% (n=15)
NCT02001623 · Phase 1/2 · monotherapy
13% (n=15)
NCT02001623 · Phase 1/2 · monotherapy
14% (n=36)
NCT02001623 · Phase 1/2 · monotherapy
0% (n=18)
NCT02001623 · Phase 1/2 · monotherapy
Disease Control 50% (n=6) @ 6wk2.2 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT02001623 · Phase 1/2 · monotherapy
show 59 more results
0% (n=6) @ 12wk2.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=6) @ 24wk2.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=6) @ 36wk2.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
67% (n=3) @ 6wk2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 12wk2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 24wk2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 36wk2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
100% (n=3) @ 6wk1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
67% (n=3) @ 12wk1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 24wk1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 36wk1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 6wk1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 12wk1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 24wk1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 36wk1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
67% (n=3) @ 6wk1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
67% (n=3) @ 12wk1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 24wk1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 36wk1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 6wk0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 12wk0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 24wk0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 36wk0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 6wk0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 12wk0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 24wk0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
33% (n=3) @ 36wk0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 6wk0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 12wk0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 24wk0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
0% (n=3) @ 36wk0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy
47% (n=15) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
60% (n=55) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
64% (n=14) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
40% (n=15) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
60% (n=15) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
72% (n=36) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
61% (n=18) @ 6wk
NCT02001623 · Phase 1/2 · monotherapy
33% (n=15) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
47% (n=55) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
43% (n=14) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
20% (n=15) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
13% (n=15) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
42% (n=36) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
28% (n=18) @ 12wk
NCT02001623 · Phase 1/2 · monotherapy
20% (n=15) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
18% (n=55) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
21% (n=14) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
7% (n=15) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
13% (n=15) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
14% (n=36) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
6% (n=18) @ 24wk
NCT02001623 · Phase 1/2 · monotherapy
7% (n=15) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
11% (n=55) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
0% (n=14) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
0% (n=15) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
7% (n=15) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
3% (n=36) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
6% (n=18) @ 36wk
NCT02001623 · Phase 1/2 · monotherapy
PFS 2.61 months2.2 mg/kg
time to event · months
No placebo or comparator arm
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 11.3 weeks as posted
show 22 more results
2.84 months*2.0 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 12.3 weeks as posted
3.95 months*1.8 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 17.1 weeks as posted
1.41 months*1.5 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 6.1 weeks as posted
6.25 months*1.2 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 27.1 weeks as posted
NA months3q4wk 1.2 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence
1.41 months*0.9 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 6.1 weeks as posted
2.61 months*3q4wk 0.9 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 11.3 weeks as posted
1.38 months*0.6 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 6 weeks as posted
1.18 months*0.3 mg/kg
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 5.1 weeks as posted
2.54 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 11 weeks as posted
4.18 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 18.1 weeks as posted
NA months
NCT02001623 · Phase 1/2 · monotherapy
2.33 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 10.1 weeks as posted
3 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 13 weeks as posted
3 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 13 weeks as posted
2.98 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 12.9 weeks as posted
2.47 months*
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 10.7 weeks as posted
1.85 months*
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 8 weeks as posted
5.08 months*
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 22 weeks as posted
3.23 months*
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 14 weeks as posted
1.15 months*
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 5 weeks as posted
2.75 months*
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to months from 11.9 weeks as posted
Duration of Response NA months1.2 mg/kg
time to event · months
No placebo or comparator arm
NCT02001623 · Phase 1/2 · monotherapy
show 6 more results
7.38 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 32 weeks as posted
4.25 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 18.4 weeks as posted
NA months
NCT02001623 · Phase 1/2 · monotherapy
4.22 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 18.3 weeks as posted
NA months
NCT02001623 · Phase 1/2 · monotherapy
4.94 months*
NCT02001623 · Phase 1/2 · monotherapy · converted to months from 21.4 weeks as posted
Complete 0% (n=6)3q4wk 1.2 mg/kg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
show 8 more results
0% (n=3)*3q4wk 0.9 mg/kg
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=5)*
Complete Response
NCT03245736 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=11)*
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=3)*
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=1)*
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=5)*
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=1)*
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=3)*
Complete Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
Partial 16.7% (n=6)3q4wk 1.2 mg/kg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
show 8 more results
0% (n=3)*3q4wk 0.9 mg/kg
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
40% (n=5)*
Partial Response
NCT03245736 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
27.3% (n=11)*
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 participants as posted
33.3% (n=3)*
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
100% (n=1)*
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
40% (n=5)*
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 participants as posted
0% (n=1)*
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=3)*
Partial Response
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
Stable Disease 50% (n=6)3q4wk 1.2 mg/kg
event count · % of participants
No placebo or comparator arm
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 participants as posted
show 8 more results
66.7% (n=3)*3q4wk 0.9 mg/kg
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 participants as posted
40% (n=5)*
Stable Disease
NCT03245736 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
27.3% (n=11)*
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 participants as posted
0% (n=3)*
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
0% (n=1)*
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
40% (n=5)*
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 participants as posted
0% (n=1)*
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
66.7% (n=3)*
Stable Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 participants as posted
Progressive Disease 16.7% (n=6)3q4wk 1.2 mg/kg
event count · % of participants
No placebo or comparator arm
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
show 8 more results
33.3% (n=3)*3q4wk 0.9 mg/kg
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
20% (n=5)*
Progressive Disease
NCT03245736 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
18.2% (n=11)*
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 participants as posted
66.7% (n=3)*
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 participants as posted
0% (n=1)*
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 participants as posted
20% (n=5)*
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
100% (n=1)*
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
33.3% (n=3)*
Progressive Disease
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 participants as posted
ORR 50% (n=6)3q4wk 1.2 mg/kg
event count · % of participants
No placebo or comparator arm
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 1 more result
33.3% (n=3)*3q4wk 0.9 mg/kg
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted
Tumor Size -17.34% (n=11)
percent change · % of baseline
No placebo or comparator arm
NCT02552121 · Phase 1/2 · registry result, not featured evidence
show 5 more results
32.78% (n=3)
NCT02552121 · Phase 1/2 · registry result, not featured evidence
-63.27% (n=1)
NCT02552121 · Phase 1/2 · registry result, not featured evidence
0.74% (n=5)
NCT02552121 · Phase 1/2 · registry result, not featured evidence
0% (n=1)
NCT02552121 · Phase 1/2 · registry result, not featured evidence
11.76% (n=3)
NCT02552121 · Phase 1/2 · registry result, not featured evidence
Disease Control 50% (n=6) @ 6wk3q4wk 1.2 mg/kg
event count · % of participants
No placebo or comparator arm
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 7 more results
66.7% (n=3) @ 6wk*3q4wk 0.9 mg/kg
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted
54.5% (n=11) @ 6wk*
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 6 Participants as posted
33.3% (n=3) @ 6wk*
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted
100% (n=1) @ 6wk*
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted
80% (n=5) @ 6wk*
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 4 Participants as posted
0% (n=1) @ 6wk*
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
66.7% (n=3) @ 6wk*
6 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted
Disease Control 0% (n=6) @ 12wk3q4wk 1.2 mg/kg
event count · % of participants
No placebo or comparator arm
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 7 more results
0% (n=3) @ 12wk*3q4wk 0.9 mg/kg
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
18.2% (n=11) @ 12wk*
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted
33.3% (n=3) @ 12wk*
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted
100% (n=1) @ 12wk*
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted
40% (n=5) @ 12wk*
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted
0% (n=1) @ 12wk*
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
33.3% (n=3) @ 12wk*
12 Weeks · Disease Control - Yes
NCT02552121 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: STRO-004's landscape · Tisotumab Vedotin Humax-tf-adc's landscape